In NSCLC, Cluster of Differentiation 200 (CD200)-expressing CAFs have been found to increase tumor cell sensitivity to targeted therapies, such as Epidermal Growth Factor Receptor (EGFR) inhibitors, and this effect disappears when CD200 is absent [81]. This evidence concerns the gene CD200 and neoplasm.